Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results  by Orlic, Dejan et al.
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OBJECTIVES This study evaluated clinical outcome after multivessel stenting with sirolimus-eluting stents
(SES) in unselected lesions.
BACKGROUND Safety and effectiveness of multivessel SES implantation is currently unknown.
METHODS Major adverse cardiac events (MACE) (death, myocardial infarction [MI], and repeat
revascularization) were analyzed at 30 days and at 6 months after multivessel SES
implantation.
RESULTS In 155 consecutive patients, 573 SES were implanted in 3.3  1.3 lesions per patient. At 30
days, the cumulative MACE rate was 10.3%: 7.1% patients developed a non–Q-wave MI,
1.9% developed a Q-wave MI, 0.6% died for non-cardiac reasons, and 0.6% had a repeat
revascularization. Clinical follow-up was obtained in all 112 eligible patients treated for 359
lesions at a mean time of 6.5 2.2 months. The cumulative MACE rate was 22.3%: 3 (2.7%)
deaths (1 for cardiac reasons), 4 (3.6%) MIs, target lesion revascularization (TLR) in 16
(14.3%) patients with 24 (6.7%) lesions. Target vessel revascularization was required in 18
(16.1%) patients due to TLR of lesions treated with SES or to disease progression (1.8% of
patients). Cox regression analysis revealed total stent length per patient as the most powerful
independent predictor of MACE. Overall stent thrombosis occurred in three (1.9%) patients.
CONCLUSIONS Multivessel SES implantation can be safely performed on patients with complex coronary
artery disease. The need for revascularization increases because of the cumulative effect of
TLR on patients with multiple lesions. (J Am Coll Cardiol 2004;43:1154–60) © 2004 by
the American College of Cardiology Foundationp
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cbservational and randomized studies comparing outcome
etween stented and surgically treated patients with mul-
ivessel disease reported higher restenosis and repeat revas-
ularization rates in patients treated with bare metal stents
BMS) than in those after surgical treatment (1–5). In
eported randomized studies, treatment of stenotic lesions
n native coronary arteries by implantation of the sirolimus-
luting stent (SES) (Cypher, Cordis, a J&J, Warren, New
ersey) (6,7) or the paclitaxel-eluting stent (Taxus, Boston
cientific, Natick, Minnesota) (8) showed a low percent of
ngiographic restenosis and additional revascularization.
owever, in the Randomized Study with the Sirolimus-
oated Bx Velocity Balloon-Expandable Stent in the Treat-
ent of Patients with de Novo Native Coronary Artery
esions (RAVEL) trial, only patients with a single lesion in
ne vessel were included (6). In the U.S. Multicenter,
andomized, Double-Blind Study of the Sirolimus-Eluting
tent in De Novo Native Coronary Lesions (SIRIUS) trial,
5.3% of the patients had two-vessel disease, and 15.4% had
hree-vessel disease in the sirolimus arm, but only one lesion
From *EMO, Centro Cuore Columbus Hospital, Milan, Italy; †San Raffaele
ospital, Milan, Italy; and ‡Institute of Medical Statistics and Biometry, University
f Milan, Milan, Italy.
Manuscript received June 16, 2003; revised manuscript received October 17, 2003,eccepted October 20, 2003.er patient was treated with the SES (7). In the recently
ublished study, A Paclitaxel-Eluting Stent for the Preven-
ion of Coronary Restenosis (ASPECT), in the arm with
igh dose of paclitaxel, 33% of the patients had two-vessel
isease, 13% had three-vessel disease, and 7% had complex
esions (9).
No study was specifically dedicated to evaluate the effec-
iveness of drug-eluting stents in patients with multivessel
isease. We report safety and clinical effectiveness of mul-
iple SES implantations in patients with multivessel coro-
ary artery disease.
ETHODS
atients and lesions. For this analysis, all consecutive
atients who were referred to our center between April 16,
002, and March 5, 2003, and underwent elective percuta-
eous coronary intervention (PCI) with multivessel stenting
sing SES were selected. Patients included in this study had
ither stable or unstable angina, or silent ischemia and at
east two lesions located in different vessels treated with
ES. Different vessels were defined as involvement of two
ajor epicardial vessels (right, left anterior descending,
ircumflex, or left main coronary arteries) (10) or one major
picardial vessel and a branch (2.5 mm in diameter)
o
a
(
v
i
h
t
l
s
b
u
E
d
m
t
a
Q
a
v
a
M
i
s
w
(
r
d
(
H
k
r
w
2
w
i
e
n
T
t
a
A
a
w
t
M
3
t
l
m
h
q
a
I
o
t
t
a
Q
f
s
h
T
u
5
d
t
l

s

g
F
p
A
m
t
S
f
v
v
b
u
u
W
i
r
s
p
f
R
A
1155JACC Vol. 43, No. 7, 2004 Orlic et al.
April 7, 2004:1154–60 Multivessel Stenting With SESriginating from another major epicardial vessel. Occasion-
lly, conventional percutaneous coronary angioplasty
PTCA) was performed without stent implantation in
essels 1.5 to 2.5 mm. Stenting procedures were performed
n the usual fashion (11). All stents were implanted with
igh pressure (12 atm) final stent dilation with an attempt
o fully cover the angiographic lesion with the stent. For
esions located at the bifurcation site, the T or the Crushing
tenting techniques (12,13) were utilized to treat the main
ranch and the side branch. Intravascular ultrasound was
sed only according to the decision of the operator.
nd points and definitions. The aim of our study was to
etermine procedural success, composite 30-day and six-
onth major adverse cardiac events (MACE) after mul-
ivessel SES implantation. Procedural success was defined as
ngiographic success without death, non–Q-wave or
-wave myocardial infarction (MI), emergency coronary
rtery bypass grafting (CABG), or repeat PCI of the target
essel before discharge. Angiographic success was defined as
final diameter stenosis of 30% with a Thrombolysis In
yocardial Infarction (TIMI) flow rate of grade 3 accord-
ng to TIMI trial. Composite 30-day MACE reflects the
afety of the procedure, and was defined as death, non–Q-
ave or Q-wave MI, or target lesion revascularization
TLR) (CABG or repeat PCI). Six-month rate of MACE
eflects clinical effectiveness of the procedures and was
efined as death, MI, or target vessel revascularization
TVR). Non–Q-wave MI was defined according to World
ealth Organization definition: increase of total creatine
inase (CK) two times or more the upper limit of normal
ange with an elevated MB isoform level (mass analysis)
ithout development of new Q waves (more than 0.04 s in
or more contiguous leads). A Q-wave MI was present
hen, in addition to CK elevation, there were new Q waves
n at least two leads. In all patients, CK and CK-MB were
valuated every 6 h three times after the procedure or until
ormalization if they were elevated.
Complete revascularization was defined as restoration of
IMI 3 flow with residual stenosis 30% to all myocardial
Abbreviations and Acronyms
BMS  bare metal stent
CABG  coronary artery bypass grafting
CK  creatine kinase
MACE  major adverse cardiac events
MI  myocardial infarction
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
SES  sirolimus-eluting stent
SIRIUS  U.S. Multicenter, Randomized, Double-Blind
Study of the Sirolimus- Eluting Stent in De
Novo Native Coronary Lesions
TLR  target lesion revascularization
TVR  target vessel revascularizationerritories. Complex lesions were defined as type B2 or C pccording to modified American College of Cardiology/
merican Heart Association classification (14).
Stent thrombosis was defined as occlusion or filling defect
t the stent site documented by angiography or chest pain
ith electrocardiographic changes suggestive of MI in the
erritory of the stented vessel or occurrence of sudden death.
edical therapy. Antiplatelet therapy with aspirin (100 to
25 mg every day) and thienopyridines (ticlopidine 250 mg
wice a day or clopidogrel 75 mg every day) was started at
east three days before the procedure. A loading dose of 300
g of clopidogrel was given in all other cases. Intravenous
eparin (70 to 100 IU/kg) and additional boluses, if re-
uired to maintain activated coagulation time 250 s, were
dministered after a sheath insertion. Use of glycoprotein
Ib/IIIa receptor inhibitors was left to the decision of the
perator. Aspirin and clopidogrel were continued for at least
hree months or up to six months to one year when more
han two stents were implanted or a vessel was stented over
segment longer than 33 mm.
uantitative angiographic analysis. Angiograms suitable
or quantitative analysis were obtained both before and after
tent implantation using the same angiographic view that
ad revealed the greatest stenosis in the stented segment.
he analysis was done with a computer-assisted system
sing an automated edge detection algorithm (CMS version
.0 and 5.2, MEDIS, Leiden, the Netherlands). The outer
iameter of the contrast-filled catheter was used for calibra-
ion. Regarding the angiographic pattern of restenosis, focal
esion was defined as lesion length 10 mm, multifocal as
1 focal lesion in the same stented segment with normal
egment in between, and diffuse restenosis as lesion length
10 mm. Relative gain was defined as ratio between acute
ain and reference vessel diameter.
ollow-up. Clinical follow-up was obtained by direct tele-
hone interview with the patient at one and at six months.
ngiographic follow-up was suggested between 8 and 12
onths after stenting unless clinically indicated at an earlier
ime.
tatistical analysis. Descriptive statistical analysis was per-
ormed by using continuous variables expressed as mean
alue  1 standard deviation and by using categorical
ariables presented as percent frequency. For comparison
etween groups with categorical data, chi-square testing was
sed. The Cox proportional-hazards regression model was
sed to determine independent predictors of MACE. The
ald test was used to determine the importance of the
ndividual coefficient. A p value lower than 0.05 was
equired for statistical significance. Kaplan-Meier event-free
urvival curves were constructed. Statistical analysis was
erformed with commercially available software (SPSS 11
or Windows, SPSS Inc., Chicago, Illinois).
ESULTS
total of 511 lesions were treated with 573 SES in 155
atients. A mean of 3.6 1.5 lesions per patient underwent
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Multivessel Stenting With SES April 7, 2004:1154–60tent implantation (SES or bare-metal stent [BMS]) or
TCA, and in 3.3  1.3 lesions, SES were implanted (87%
f the treated lesions). A total of 37 BMS were implanted in
roximal parts of large vessels. Plain balloon angioplasties
ere performed without stent implantation in small vessels:
istal vessel segments or small side branches of bifurcation
esions (40 lesions). Complete revascularization was
chieved in 109 (70.3%) patients.
rocedure. Sirolimus-eluting stents were successfully de-
loyed to all the lesions with final angiographic success in
08 (99.4%) lesions. In one case (lesion located at distal
essel segment), abrupt closure of the vessel segment distal
o the implanted SES occurred and was left untreated; in
he other two lesions, final diameter stenosis was more than
0%.
atients and lesion characteristics. Patient characteristics
re reported in Table 1. A total of 74 (47.7%) patients had
revious MI. Low ejection fraction of the left ventricle
35%) was found in 8 (5.2%) patients. Two-vessel disease
as found in 67 (43.2%) patients, and three-vessel disease in
8 (56.8%) patients. Two-vessel SES implantation was
erformed in 128 patients (400 lesions), and three-vessel
ES in 27 patients (111 lesions). The qualitative angio-
raphic results are reported in Table 2. Lesions were located
n the left anterior descending coronary artery (40.1%)
redominantly in proximal or mid-segments of the treated
essel (66.2%). Eighty-one (15.8%) lesions were located in
stial/proximal segments of the left anterior descending
oronary artery. There was a high percentage (81.4%) of
omplex lesions. Unprotected left mains were treated in
even patients. A relatively high proportion of 200 (39.1%)
esions were located in small vessels (reference vessel diam-
ter 2.5 mm). Among 87 bifurcation lesions, both
ranches were treated with the SES deployment in 76
87.4%) lesions.
uantitative angiographic results. Table 3 reports the
able 1. Baseline Clinical Characteristics
SES
(n  155 Patients)
ge, yrs 61.2  10.6
en, % 146 (94.2%)
urrent smoker, % 18 (11.6%)
ypercholesterolemia, % 104 (67.1%)
ystemic hypertension, % 88 (56.8%)
iabetes mellitus, % 37 (23.9%)
rior CABG, % 31 (20.0%)
rior MI, % 74 (47.7%)
nstable angina, % 32 (20.6%)
wo-vessel disease, % 67 (43.2%)
hree-vessel disease, % 88 (56.8%)
eft ventricular ejection fraction, % 53.1  8.6
hree-vessel stenting, % 27 (17.4%)
atients with bifurcation lesions, % 71 (45.8%)
atients with CTO, % 28 (18.1)
alues are mean  SD or numbers and percentage of patients.
CABG  coronary artery bypass grafting; CTO  chronic total occlusion; MI 
yocardial infarction; SES  sirolimus-eluting stent.uantitative angiographic results. The reference vessel di-meter was 2.64  0.57 mm. Residual stenosis was 12.7 
.8%. The mean lesion length at baseline was 16.7  10.8
m, and 163 (31.9%) lesions were long (20 mm). Mean
ength of stented segment was 27.5  13.5 mm. After final
tent dilation, the acute gain was 1.74  0.60 mm and
elative gain 0.65  0.23.
able 2. Baseline Lesion and Procedural Characteristics
SES
(n  511 Lesions)
arget vessel, %
LM 15 (2.9%)
LAD 205 (40.1%)
LCx 164 (32.1%)
RCA 121 (23.7%)
LIMA 6 (1.2)
ocation in vessel, %
Ostial 90 (17.6%)
Proximal 192 (37.6%)
Mid 146 (28.6%)
Distal 83 (16.2%)
CC/AHA lesion type,* %
A 10 (2.0%)
B1 85 (16.6%)
B2 245 (47.9%)
C 171 (33.5%)
ifurcation, % 168 (32.9%)
n-stent restenosis, % 51 (10.0%)
alcium (moderate to severe), % 22 (4.3%)
ccentric, % 406 (79.4%)
otal occlusion, % 44 (8.6%)
retreatment, %
Plain balloon, % 368 (72.0%)
Atherectomy, % 11 (2.1%)
umber of SES per lesion 1.12  0.38
umber of SES per patient 3.29  1.27
tented segment length, mm 27.5  13.5
aximum balloon diameter, mm 2.92  0.41
aximum balloon pressure, atm 16.2  3.1
sage of IIb/IIIa inhibitor, % of patients 92 (59.3%)
ABP, % of patients 3 (1.9%)
sage of IVUS, % of lesions 61 (11.9%)
alues are mean  SD and percentage of lesions. Percentages of patients are
ndicated. *Modified American College of Cardiology/American Heart Association
ACC/AHA) lesion classification.
IABP intra-aortic balloon pump; IVUS intravascular ultrasound; LAD left
nterior descending coronary artery; LCx  left circumflex coronary artery; LIMA 
eft internal mammary artery; LM left main coronary artery; RCA right coronary
rtery; SES  sirolimus-eluting stent; SVG  saphenous vein graft.
able 3. Quantitative Coronary Angiographic Results
SES
(n  511 Lesions)
aseline
Reference vessel diameter, mm 2.64  0.57
MLD, mm 0.89  0.49
Diameter stenosis, % 66.2  17.2
Lesion length, mm 16.7  10.8
inal
MLD, mm 2.62  0.49
Diameter stenosis, % 12.7  7.8
Acute gain, mm 1.74  0.60
Relative gain 0.65  0.23
alues are mean  SD of lesions.
MLD  in-lesion minimum lumen diameter; SES  sirolimus-eluting stent.
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April 7, 2004:1154–60 Multivessel Stenting With SESrocedural complications and 30-day outcomes. Pro-
edural complications and 30-day outcome are reported in
ables 4 and 5. One patient had abrupt closure of a vessel
egment distal to the SES. One patient had Q-wave MI due
o acute, periprocedural thrombosis after stent deployment
n a bifurcation lesion. After mechanical aspiration of
hrombus and adjunctive therapy with glycoprotein IIb/IIIa
eceptor inhibitor, final TIMI 3 flow was restored. In one
atient, urgent PCI was performed 2 h after the procedure
ecause of chest pain associated with ST-segment elevation.
ritical stenosis due to dissection at the distal margin of the
ES was successfully treated by additional stent implanta-
ion. No patient died while in the hospital, and no patient
equired emergent surgical revascularization.
A total of 11 (7.1%) patients developed a non–Q-wave
I, and two patients (1.2%) had a Q-wave MI. Rise of
K-MB 3 times the upper normal range was found in 26
16.8%) patients after the procedure. Increase in CK-MB
3 times the upper normal limit occurred in 17 (12.8%)
atients with two-vessel SES implantation and in 9 (32.1%)
atients (p  0.025) with three-vessel SES implantation.
No patient developed major hematoma requiring trans-
usion, pseudoaneurysm, or need for vascular repair at the
ccess site.
After the discharge, within 30-day clinical follow-up, one
atient died because of intracranial bleeding. One patient
ad a Q-wave MI 10 days after discontinuation of clopi-
ogrel because of urgent abdominal operation. In this
eriod, no repeat revascularization was required.
ix-month clinical outcome. A total of 112 patients (359
esions) eligible for 6-month clinical follow-up completed a
ean follow-up time of 6.5  2.2 months (range, 1.8 to
3.2 months). Table 6 reports the specific adverse events
able 4. Procedural Success and Complications
SES
(n  511 Lesions)
ngiographic success, % 99.4
rocedural success, % 91.3
brupt vessel closure, % 1 (0.6%)
cute thrombosis, % 1 (0.6%)
ny procedural complication, % 2 (1.2%)
alues are percentage of lesions.
SES  sirolimus-eluting stent.
Table 5. In-Hospital and 30-Day Outcome
In-Hospital MACE*
(n  155 Patients)
Death, % 0
Q-wave MI, % 2 (1.2%)
Non–Q-wave MI, % 11 (7.1%)
Repeat PCI, % 1 (0.6%)
Emergent CABG, % 0
Total MACE, % 14 (9.0%)
Values are numbers and percentages of patients. *MACE inc
target vessel revascularization; †subacute thrombosis.
CABG  coronary artery bypass grafting; MACE  m
percutaneous coronary intervention; UNL  upper normal limit.hat occurred during this follow-up. Two patients died: one
atient two months after the index procedure because of
cute MI at 10 days after unplanned suspension of clopi-
ogrel; the other patient died three months after the
rocedure because of vascular complications after surgical
epair of abdominal aortic aneurysm. One patient had MI
.7 months after the index procedure. Target lesion revas-
ularization was required in 24 (6.7%) lesions in 16 (14.3%)
atients. Target vessel revascularization, including non-
arget sites, was required in 18 (16.1%) patients. It is
mportant to mention that all revascularization events were
ue to TLR of lesions treated with SES or to disease
rogression. No revascularization was required in segments
reated by PTCA or BMS. Cumulative MACE occurred in
5 (22.3%) patients. The different clinical outcomes are
llustrated by the Kaplan-Meier estimates of event-free
urvival among patients who reached 250-day follow-up
ithout TLR (Fig. 1A), without TVR (Fig. 1B), or without
ACE (Fig. 1C).
Cox regression analysis was used to identify independent
redictors for cardiac events. Independent predictors of
ccurrence of TLR were reference vessel diameter (hazard
atio  0.346, p  0.0280) and final minimum lumen
iameter (hazard ratio  0.359, p  0.0058). Predictors of
VR were: final minimum lumen diameter (hazard ratio 
.228, p  0.04), total stent length per patient (hazard ratio
1.010, p  0.02), and maximum stent length per vessel
0-Day MACE
 155 Patients)
Composite 30-Day MACE
(n  155 Patients)
1 (0.6%) 1 (0.6%)
1 (0.6%)† 3 (1.9%)
0 11 (7.1%)
0 1 (0.6%)
0 0
2 (1.3%) 16 (10.3%)
death, Q-wave and non–Q-wave myocardial infarction, and
verse cardiac events; MI  myocardial infarction; PCI 
able 6. Six-Month Clinical Outcome
End Point
SES
n  112 Patients
359 Lesions
eath, % of patients 3 (2.7%)
yocardial infarction Q-wave, % of patients 4 (3.6%)
erebrovascular accidents, % of patients 0
LR, % of lesions 24 (6.7%)
PCI, % 20 (5.6%)
CABG, % 4 (1.1%)
LR, % of patients 16 (14.3%)
VR, % of patients 18 (16.1%)
umulative MACE*, % of patients 25 (22.3%)
alues are numbers and percentages of patients or lesions when indicated.
CABG  coronary artery bypass grafting; MACE  major adverse cardiac events
death, myocardial infarction, or target vessel revascularization); PCI  percutaneous
oronary intervention; SES  sirolimus-eluting stent; TLR  target lesion revascu-
arization; TVR  target vessel revascularization.3
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Multivessel Stenting With SES April 7, 2004:1154–60hazard ratio  1.013, p  0.04). Predictors of MACE
ere: diabetes (hazard ratio  2.406, p 0.04), total stent
ength per patient (hazard ratio  1.009, p  0.02), and
aximum stent length per vessel (hazard ratio 1.012, p
.03) (Table 7). Variables included in this model were:
igure 1. Kaplan-Meier estimates of the probability of survival without
arget lesion revascularization (TLR) (A), without target vessel revascular-
zation (TVR) (B), and without cumulative total major adverse cardiac
vents (MACE) (C).nstable angina, diabetes, complex lesions (type C according to modified American College of Cardiology/American
eart Association classification), reference vessel diameter,
esion length, three-vessel stenting, final minimum lumen
iameter, stent length per lesion, and total stent length per
atient as potential predictors of TLR, and additionally,
aximum stent length per vessel for TVR and MACE.
Angiographic follow-up was performed in 27 patients (93
esions). Clinically driven follow-up angiography was per-
ormed in 11 patients, and routine control follow-up an-
iography in 16 patients. Total occlusion of the stented
essel was found in two patients: one asymptomatic and one
ith effort angina. In the other 25 patients (86 lesions),
estenosis (50% of diameter stenosis) was found in 14
atients (24 lesions). Pattern of restenosis was focal in 23
esions and diffuse in one lesion. Among focal lesions, four
ere multifocal. All restenotic lesions occurred in the
tented segment. Revascularization of the restenostic lesions
as performed in all 24 lesions, while the two total
cclusions were not revascularized. There were no patients
ith revascularization of the non-target vessel alone.
ncidence of stent thrombosis. Of 155 patients treated
ith SES, a total of two documented thrombotic events and
ne possible thrombosis occurred. One of them was acute
nd intraprocedural, one subacute (28 days) associated with
I and stent occlusion, and one possible late thrombosis
54 days) was associated with sudden death. In the last two
atients, clopidogrel was discontinued seven to 10 days
efore the events.
ISCUSSION
he major findings of this study evaluating the outcome of
atients after multivessel SES implantation are: the MACE
ates at 30 days appear low and comparable to other studies
valuating a less complex population (4,13); at a mean
ollow-up of 6.5 months, the 22.3% MACE rate is mainly
riven by a 16% need for revascularizations; despite the fact
hat TLR remains low (6.7%), the increase in need for
evascularization per patient occurs due to treatment of
ultiple lesions.
A mean of 3.3 1.3 lesions per patient were treated with
ES implantation, more than in major trials: 2.7 lesions in
he Stent Or Surgery (SOS) trial and 2.6 lesions in the
rterial Revascularization Therapies Study (ARTS). An-
iographic success of 99.4% is comparable with the range
rom 97% to 100% achieved with bare metal multivessel
tenting in observational (4,5,15,16) and randomized (1,2)
tudies. Complete revascularization was achieved in 70.3%
atients, as in one major randomized trial (17). The lesions
reated with SES implantation in this report are character-
zed by high percentages of complex lesions (81%), long
esions (32%), and lesion site in vessels 2.5 mm (39%).
he rate of MI was acceptable: 7.1% for a non–Q-wave MI
nd 1.2% for a Q-wave MI.
When we look at all post-procedural rises of CK-MB3imes the upper normal range, this complication was found
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April 7, 2004:1154–60 Multivessel Stenting With SESn 26 (16.8%) of our patients. In the ARTS study, the
bnormal level of CK-MB was observed in 31% of patients
n the stenting arm (1). This difference may be explained by
he more liberal use of glycoprotein IIb/IIIa receptor inhib-
tors in our study (59.3%), compared with the 8% in the
OS trial (2) and almost no usage in the ARTS trial. More
requent rises in CK-MB 3 times the upper normal range
ere found among patients with three-vessel SES implan-
ation compared with those in whom two-vessel SES
eployment was performed (32.1% vs. 12.8%, p  0.025).
his finding may imply a need for a more liberal elective use
f glycoprotein IIb/IIIa receptor inhibitors when three-
essel SES implantation is planned.
The fact that the early outcome remained similar to that
n previous reports dealing with less complex patient cohorts
1,2,5) testifies to the overall improvement in the safety and
uccess of PCI procedures over the past years.
ACE at six months. The 22.3% MACE rate at an
verage follow-up time of 6.5 months may appear high in
ight of the expectations after the introduction of drug-
luting stents. The fact that the main determinant of late
vents was the need for new revascularization points to three
onsiderations: 1) when the operator has a device available
uch as a drug-eluting stent that is supposed to deliver a very
ow restenosis rate, the tendency to treat more lesions
ncreases; 2) when these stents are implanted in complex
esions, their performance is inferior to the performance
eported in randomized trials; and 3) the relatively low
estenosis rate per lesion reported in randomized trials adds
p when multiple lesions are treated in the same patient.
When restenosis was detected, its pattern was focal in
ost of the lesions, a situation that should make re-
ntervention easier. The fact that all restenoses occurred
nside the stents was probably due to our strategy to use
onger stents and to pay attention to fully cover the diseased
egment. A prior study from our laboratory evaluating BMS
mplantation in multivessel disease reported a 30% six-
onth need for re-interventions on target vessels (5) com-
ared with 16% in the present study.
Table 7. Predictors of TLR, TVR, and MACE
Variables
Hazard
Ratio
TLR
Reference vessel diameter 0.346
Final minimum lumen diameter 0.359
TVR
Final minimum lumen diameter 0.228
Total stent length per patient 1.010
Maximum stent length per vessel 1.013
Total MACE
Diabetes 2.406
Total stent length per patient 1.009
Maximum stent length per vessel 1.012
MACE  major adverse cardiac events; MLD  in-lesion
TVR  target vessel revascularization.Regression analysis revealed that reference vessel size andnal minimum lumen diameter were associated with in-
reased risk for TLR. The higher risk of restenosis in small
essels was also reported in a subanalysis of the SIRIUS trial
7). As far as the total stent length per patient and the
aximum stent length per vessel being predictors of TVR,
e believe that these two parameters reflect the lesion
omplexity and the extension of the disease burden at risk
or restenosis and re-intervention. Among the clinical vari-
bles, the fact that diabetes mellitus was a predictor of total
ACE confirms the importance of this risk factor. Con-
erns may arise about the conservative use of glycoprotein
Ib/IIIa inhibitors in these patients in our study (23 of 37,
2.2%).
hrombotic events. Considering the complex patient
opulation treated, there was a low incidence of thrombotic
vents. In particular, all subacute thrombosis occurred in
wo patients who stopped clopidogrel before the date
rescribed. There were two late SES occlusions detected at
ollow-up angiography, which were not associated with any
cute event, and we cannot determine if thrombosis
ccurred.
tudy limitations. Important limitations of this report are
he limited number of patients available for clinical
ollow-up and the low number of elective angiographic
ollow-ups performed. Despite these shortcomings, the
nitial observations are important because they help to place
he SES in the appropriate perspective when they are used
n patients who are potentially surgical candidates.
onclusions. Use of the SES allows safe treatment of
atients with complex coronary artery disease. The persis-
ence of new revascularization procedures during the
ollow-up suggests the need for a better understanding of
he reasons for the failure to further improve the percuta-
eous approach in most patients with multivessel coronary
rtery disease.
eprint requests and correspondence: Dr. Antonio Colombo,
MO Centro Cuore Columbus, Via Buonarroti 48, Milan, Italy.
-mail: info@emocolumbus.it.
Cox Regression Analysis
5% Lower
fidence Limit
95% Upper
Confidence Limit p Value
0.134 0.892 0.028
0.174 0.744 0.006
0.054 0.969 0.045
1.001 1.020 0.024
1.001 1.026 0.037
1.037 5.583 0.041
1.001 1.017 0.022
1.001 1.023 0.027
al lumen diameter; TLR  target lesion revascularization;by
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